Abstract: The novel compounds of the formulas I and I' ##STR1## wherein F is in 5 or 6 position and ##STR2## wherein in both formulas R is the group --CH.sub.2 OCOOR.sup.1, wherein R.sup.1 is a straight or branched alkyl containing 1-6 carbon atoms or benzyl, or R.sup.1 is the group ##STR3## wherein n is 1-6 and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine.

Abstract: The novel compounds of the formulas I and I' ##STR1## wherein F is in 5 or 6 position and ##STR2## wherein in both formulas R is the group --CH.sub.2 OCOOR.sup.1, wherein R.sup.1 is a straight or branched alkyl containing 1-6 carbon atoms or benzyl, or R.sup.1 is the group --(CH.sub.2).sub.n ##STR3## --(CH.sub.2).sub.n COOH or --(CH.sub.2).sub.n SO.sub.3 H wherein n is 1-6 and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine.

Abstract: A particle containing a liquid-soluble active substance for release outside a human or animal body, said particle comprising a core with a coating thereon, said coating comprising a liquid soluble active substance, is characterized in that the core has an appearance differing from the appearance of the coating, and that the appearance of the core is initially concealed by the coating and appears after dissolution of the liquid-soluble active substance, thus indicating that the active substance in said coating has been dissolved. The invention has its foremost application on granules, tablets and similar drug releasing units which make part of a parenteral liquid administration device.

Abstract: Controlled release preparation containing a number of insoluble beads applied with one or more pharmaceutically active compounds, a method for the production thereof and the use in a treatment where a controlled release of a pharmaceutically active compound is needed.

Abstract: Novel compounds of the formula ##STR1## pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine for treating gastric acid related diseases such as gastritis, gastric ulcer, duodenal ulcer and reflux esophagitis.

Abstract: A device for release of a solid substance into a flowing liquid during parenteral administration of the liquid to a patient includes a connector (1, with an inlet (6) and an outlet (12) for the liquid, and a valve assembly (4,5). The valve assembly has a valve core (5) which is rotatable between a bypass position and a working position. A releasable container (15), containing the solid substance, may be connected to the valve core (5). In the bypass position, liquid is conducted from the inlet to the outlet, by-passing the container (15). When the valve core (5) is moved to the working position, liquid is diverted into the container (15), for mixing with the solid substance, and then returned to the connector, where it then exits through the outlet (12).

Abstract: A compound of the formula ##STR1## and when appropriate in the form of a racemic mixture or in the form of a stereoisomeric component and the pharmaceutically acceptable salts thereof, in which formulan is an integer 0, 1 or 2Y is [CH.sub.2 ].sub.m, CHOH, CHOCH.sub.3, CHNHR or CHF,m is an integer 0 or 1 andR is hydrogen, methyl or ethyl,Z is hydrogen or a saturated or unsaturated, straight or branched alkyl group containing 1-3 carbon atoms,A is a group ##STR2## wherein R.sub.a is a straight or branched hydroxyalkyl or an alkyl group containing 1-5 carbon atoms and optionally substituted by one or more fluoro atoms,R.sub.c is a saturated or unsaturated, straight or branched alkyl group containing 1-4 carbon atoms and optionally substituted by one or more fluoro atoms,R.sub.a' is the same as Ra and independently of R.sub.a",R.sub.a" is the same as Ra and independently of R.sub.

Abstract: Almokalant (p-INN), 4-[3-]ethyl[3-(propylsulfinyl)propyl]amino[-2-hydroxypropoxy]-benzonitrile , having the formula ##STR1## is a member of a group of compounds useful in the treatment of cardiac arrhythmias. Enhanced stability, palatability, and technical properties of almokalant can be achieved when it is complexed as a salt with polystyrenesulfonic acid. Accordingly, the invention encompasses the almokalant salt and processes for the preparation of said salt. The invention further encompasses solid oral pharmaceutical dosage forms containing the almokalant-polystyrenesulfonate complex as well as methods for their manufacture as medicaments with action against cadiac arrhythmias.

Abstract: Novel compounds of the general formula I ##STR1## processes for its preparation, pharmaceutical compositions containing such compounds as the active ingredient and the use of the compounds in medicine.

Abstract: Use of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benz imidazole or a pharmaceutically acceptable salt thereof in the treatment of infectious diseases, especially such caused by Campylobacter pylori.

Abstract: The present invention relates to metoprolol succinate, a new therapeutically active compound, and pharmaceutical preparations comprising this new compound.

Abstract: A method for the treatment of diseases related to an increased intraocular pressure in the eye comprising administration to a patient suffering therefrom an amount of a compound of the formula I ##STR1## or a pharmaceutically acceptable salt thereof.

Abstract: A salt of 4-[3-[3-[ethyl-[3-(propylsulfinyl)propyl]amino]-2-hydroxyproproxy]-benzoni trile having the formula I ##STR1## with polystyrenesulponic acid, which is useful for the treatment of cardiac arrhythmia, process for the preparation of said salt as well as the use of said salt for the preparation of medicaments with action against cardiac arrhythmias.

Abstract: 4-[3-[ethyl[3-((R*)-propylsulfinyl)propyl]amino]-2(R)-hydroxypropoxy]-benzo nitrile,4-[3-[ethyl[3-((S*)-propylsulfinyl)propyl]amino]-2(R)-hydroxypropoxy]-benzo nitrile,4-[3-[ethyl[3-((R*)-propylsulfinyl)propyl]amino]-2(S)-hydroxypropoxy]-benzo nitrile,4-[3-[ethyl[3-[((S*)-propylsulfinyl)propyl]amino]-2(S)-hydroxypropoxy]-benz onitrile andpharmaceutically acceptable salt thereof, processes for their preparation, as well as the use of said compounds for the preparation of medicaments with action against cardiac arrhythmias.

Abstract: The novel compounds of the formulas I and I' ##STR1## wherein F is in 5 or 6 position and ##STR2## wherein in both formulas R is the group --CH.sub.2 OCOOR.sup.1, wherein R.sup.1 is a straight or branched alkyl containing 1-6 carbon atoms or benzyl, or R.sup.1 is the group ##STR3## --(CH.sub.2).sub.n COOH or --(CH.sub.2).sub.n SO.sub.3 H wherein n is 1-6 and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine.

Abstract: The novel compound 5-fluoro-2[[(4-cyclopropylmethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimid azole and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing the compound as active ingredient, and the use of the compound in medicine.

Abstract: This application relates to novel 4 cyanophenyl derivatives which are useful for the treatment of cardiac arrhythmia and pharmaceutical compositions containing these compounds as the active ingredients.

Abstract: The novel compound 4-fluoro-2-[[(4-methoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and physiologically acceptable salts thereof as well as intermediates, pharmaceutical compositions containing such compounds as active ingredient, and the use of the compound in medicine.

Abstract: Novel compounds of the formula ##STR1## pharmaceutical compositions containing such compounds as active ingredient with gastric and inhibiting effects.

Abstract: 5-Chloro-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and physiologically acceptable salts thereof as well as an intermediate, pharmaceutical compositions containing such compound as active ingredient, and the use of the compound in medicine.